Halozyme Therapeutics, Inc. (HALO) stock analysis

In our weekly check, Halozyme Therapeutics, Inc. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 3.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as HALO.

What our checks show for HALO

Red flags

Warning signs

Strengths

Similar companies

TECH · SMMT · BMRN · KYMR · PCVX · MDGL

Questions

What grade does Halozyme Therapeutics, Inc. (HALO) have?

In our weekly check, Halozyme Therapeutics, Inc. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 20 pass, warnings: 1, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of HALO stock?

This week's biggest flags for Halozyme Therapeutics, Inc.: Margins falling, Deep past fall, Slow recovery after falls. In total 4 of 24 checks show a warning or a red flag.

What does Halozyme Therapeutics, Inc. do?

Halozyme Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as HALO.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis